论文部分内容阅读
本文系统观察诺和龙 (N组 )与格列吡嗪 (G组 )的药效动力学。初期疗程 1 2周显示两组均有明显相似的降糖效应 ,但 2h胰岛素的增幅G组高于N组。第二期将未理想达标者改为联合治疗 ,N组及G组分别加用格华止及α -GI各 1 2周 ,各时相血糖均进一步下降 ,而胰岛素的增幅减小。第三期中止联合治疗恢复原先单一治疗继续观察约半年 ,N组血浆胰岛素又复回升 ,血糖相应地继续缓慢下降 ;而G组胰岛素回升值不及N组明显 ,血糖回升至接近 9月前的水平 ,提示格列吡嗪有继发失效倾向。 7例诺和龙和格列吡嗪血糖与血浆胰岛素多时相测定的交叉对照试验显示 ,诺和龙与格列吡嗪降糖的峰值相似 ,但前者始于 1h ,后者始于 2h ,血糖下降的AUC0～ 4h相似( 4 3vs4 2mmol·h/L) ;胰岛素升高的峰值也近似 ,但前者始于 1 /2～ 1h ,3h后基本消失 ,后者始于 2h ,且持续增高 ,胰岛素升高的AUC0～ 4h格列毗哼高于诺和龙 ( 2 6 3vs 1 8 3μU·h/L)P <0 0 5。结论 :诺和龙刺激胰岛素分泌模拟生理模式 ,致使餐后早期分泌胰岛素和降糖 ,从而减轻胰岛 β细胞过度负荷并取得整体血糖的控制 ,因而可望延缓 β细胞功能的衰竭。
This article systematically observed Novozymes (N group) and glipizide (G group) pharmacodynamics. The initial course of 12 weeks showed that both groups had a significant similar hypoglycemic effect, but the increase of 2h insulin group was higher than that of N group. In the second phase, the unqualified patients were changed to the combination therapy. In the N and G groups, respectively, Gefitinib and α-GI were added for 12 weeks. The blood sugar in each phase decreased further while the increase in insulin decreased. The third phase of the combination therapy to resume the previous single treatment continue to observe about six months, N plasma insulin levels rise again, correspondingly continued to decline in blood glucose; and G group insulin recovery value less obvious than the N group, blood glucose rose to nearly 9 months ago , Suggesting that glipizide secondary failure tendency. A crossover study of 7 cases of noradrenon and glipizide and plasma insulin in a multiphase assay showed novoxamine and glipizide had similar peak hypoglycemic activity, but the former started at 1 h and the latter started at 2 h. Blood glucose (4 3vs4 2mmol · h / L). The peak of insulin rise was also similar, but the former started from 1/2 to 1h and disappeared after 3h. The latter started at 2h and continued to increase. Insulin Elevated AUC0 ~ 4h Glicipiannuo higher than noradrenonon (263vs 1 8 3μU · h / L) P <0 0 5. CONCLUSION: Novolin stimulates the physiological model of insulin secretion, resulting in the early postprandial insulin secretion and hypoglycemic, thereby reducing islet beta cell over-burden and obtaining overall blood glucose control, which is expected to delay the decline of beta-cell function.